Decentralized AI isn't just philosophically better, it's functionally necessary for science to move at the speed required. Anthropic already made Claude structurally useless for serious biotech work before any government pressure. When they launched Claude Opus 4, they activated ASL-3 — their internal Responsible Scaling Policy's highest deployed tier. The trigger? Internal testing showed the model could assist someone with a basic STEM background in synthesizing dangerous pathogens. Their chief scientist called it explicitly: COVID-like agents, pandemic-level risk. Their response was to apply broad biological research restrictions across the board. The problem is that the same guardrails that block novice bioterrorists also block legitimate computational drug discovery, protein engineering, nanobody design, and molecular pathway analysis. You can't surgically remove "dangerous biology" from "useful biology" at the model level — the underlying science is the same. So they blunted the whole thing. This is what centralized AI control looks like in practice. One company's risk tolerance — shaped by liability, regulatory pressure, and investor optics — becomes the ceiling for what an entire scientific field can access. Open source isn't just an ideological position — it's infrastructure for the next era of drug discovery.